Free Trial

Viatris (VTRS) Competitors

Viatris logo
$9.39 +0.64 (+7.31%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$9.33 -0.06 (-0.64%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

VTRS vs. PFE, ARGX, ONC, BNTX, SMMT, INSM, TEVA, GMAB, MRNA, and RDY

Should you be buying Viatris stock or one of its competitors? The main competitors of Viatris include Pfizer (PFE), argenex (ARGX), BeOne Medicines (ONC), BioNTech (BNTX), Summit Therapeutics (SMMT), Insmed (INSM), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "medical" sector.

Viatris vs. Its Competitors

Pfizer (NYSE:PFE) and Viatris (NASDAQ:VTRS) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

Pfizer presently has a consensus target price of $28.12, indicating a potential upside of 15.97%. Viatris has a consensus target price of $10.40, indicating a potential upside of 10.76%. Given Pfizer's stronger consensus rating and higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Viatris.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pfizer
1 Sell rating(s)
11 Hold rating(s)
4 Buy rating(s)
2 Strong Buy rating(s)
2.39
Viatris
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80

Pfizer has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 79.9% of Viatris shares are owned by institutional investors. 0.1% of Pfizer shares are owned by company insiders. Comparatively, 0.1% of Viatris shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Pfizer has a net margin of 16.84% compared to Viatris' net margin of -26.45%. Pfizer's return on equity of 21.42% beat Viatris' return on equity.

Company Net Margins Return on Equity Return on Assets
Pfizer16.84% 21.42% 9.12%
Viatris -26.45%16.20%7.01%

In the previous week, Pfizer had 149 more articles in the media than Viatris. MarketBeat recorded 162 mentions for Pfizer and 13 mentions for Viatris. Pfizer's average media sentiment score of 0.80 beat Viatris' score of 0.29 indicating that Pfizer is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pfizer
72 Very Positive mention(s)
33 Positive mention(s)
38 Neutral mention(s)
9 Negative mention(s)
3 Very Negative mention(s)
Positive
Viatris
1 Very Positive mention(s)
0 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pfizer has higher revenue and earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$63.83B2.16$8.03B$1.8812.90
Viatris$14.74B0.75-$634.20M-$3.17-2.96

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 7.1%. Viatris pays an annual dividend of $0.48 per share and has a dividend yield of 5.1%. Pfizer pays out 91.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Viatris pays out -15.1% of its earnings in the form of a dividend. Pfizer has increased its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Summary

Pfizer beats Viatris on 16 of the 20 factors compared between the two stocks.

Get Viatris News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VTRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VTRS vs. The Competition

MetricViatrisMedical Services IndustryMedical SectorNASDAQ Exchange
Market Cap$10.27B$7.12B$5.48B$9.57B
Dividend Yield5.49%2.83%3.99%4.18%
P/E Ratio-2.9662.8629.8725.14
Price / Sales0.7526.87422.9397.17
Price / Cash1.7226.5935.9458.58
Price / Book0.6017.548.105.59
Net Income-$634.20M$239.96M$3.26B$265.48M
7 Day Performance6.58%1.08%0.64%1.22%
1 Month Performance1.40%-3.72%2.42%0.39%
1 Year Performance-22.40%22.84%27.60%23.47%

Viatris Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VTRS
Viatris
2.6726 of 5 stars
$9.39
+7.3%
$10.40
+10.8%
-17.3%$10.27B$14.74B-2.9632,000Trending News
Earnings Report
Dividend Announcement
Short Interest ↑
Gap Up
PFE
Pfizer
4.9867 of 5 stars
$24.33
-1.9%
$28.55
+17.3%
-15.9%$138.33B$63.63B17.6381,000Trending News
Earnings Report
Analyst Forecast
Analyst Revision
ARGX
argenex
4.1148 of 5 stars
$595.19
+0.5%
$728.06
+22.3%
+35.2%$36.43B$2.58B36.721,599
ONC
BeOne Medicines
1.3153 of 5 stars
$294.51
+1.0%
$327.56
+11.2%
N/A$32.28B$3.81B-79.1711,000Trending News
Earnings Report
Analyst Forecast
Insider Trade
BNTX
BioNTech
1.9799 of 5 stars
$112.79
-2.2%
$136.58
+21.1%
+40.5%$27.11B$2.98B-33.176,772Earnings Report
Analyst Forecast
SMMT
Summit Therapeutics
2.0679 of 5 stars
$27.45
-4.3%
$34.67
+26.3%
+198.6%$20.39B$700K-80.73110Positive News
Options Volume
INSM
Insmed
3.6473 of 5 stars
$101.75
-2.1%
$109.20
+7.3%
+54.0%$19.30B$363.71M-17.101,271Earnings Report
Gap Down
TEVA
Teva Pharmaceutical Industries
2.9369 of 5 stars
$16.53
-0.1%
$24.71
+49.5%
-2.8%$18.96B$16.62B-14.3736,830Positive News
Insider Trade
GMAB
Genmab A/S
3.6707 of 5 stars
$23.09
-1.3%
$37.80
+63.7%
-14.2%$14.81B$3.12B13.122,682News Coverage
Short Interest ↑
MRNA
Moderna
4.3276 of 5 stars
$33.91
-0.7%
$46.11
+36.0%
-67.4%$13.11B$3.24B-3.885,800Trending News
Earnings Report
Analyst Revision
RDY
Dr. Reddy's Laboratories
2.3432 of 5 stars
$14.71
+0.2%
$16.95
+15.3%
-17.7%$12.28B$3.81B22.2827,811

Related Companies and Tools


This page (NASDAQ:VTRS) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners